乳癖消片治疗乳腺增生症的临床疗效及可能机制

发布时间：2019-05-24 05:02

【摘要】：目的:观察采用乳癖消片治疗乳腺增生症的临床疗效,并分析可能的疗效机制,以期为该病的临床诊疗提供参考。方法:分析2013年1月至2016年1月在某院接受诊疗的乳腺增生症患者的临床资料。依据不同的治疗方案分为观察组(乳癖消片+依西美坦)及对照组(依西美坦)。治疗8周后对比2组的临床疗效并分析可能的疗效机制。结果:本研究共纳入观察组42例,对照组45例。观察组患者治疗有效率显著高于对照组(78.6%vs.57.8%;χ2=4.304,P=0.038)。治疗后2组患者黄体生成素及孕酮水平均显著升高(P0.05),但观察组显著高于对照组(P0.05);治疗后2组患者雌二醇及催乳素水平均显著降低(P0.05),但观察组显著低于对照组患者水平(P0.05);治疗后2组患者C-反应蛋白(CRP)及白介素-6(IL-6)水平均显著降低(P0.05),但观察组显著低于对照组(P0.05)。结论:辅助使用乳癖消片治疗乳腺增生症可显著提高疗效,可能与其调节内分泌紊乱及抑制炎症反应有关。
[Abstract]:Objective: to observe the clinical efficacy of Rupixiao tablets in the treatment of breast hyperplasia and to analyze the possible therapeutic mechanism in order to provide reference for the clinical diagnosis and treatment of the disease. Methods: the clinical data of breast hyperplasia patients diagnosed and treated in a hospital from January 2013 to January 2016 were analyzed. According to different treatment schemes, they were divided into observation group (Rupixiao tablet Isimetam) and control group (Isimetam). After 8 weeks of treatment, the clinical efficacy of the two groups was compared and the possible therapeutic mechanism was analyzed. Results: a total of 42 cases in the observation group and 45 cases in the control group were included in this study. The effective rate of treatment in the observation group was significantly higher than that in the control group (78.6% vs. 57.8%; 蠂 2 鈮，

本文编号：2484583